2m 2m 2m 2m 2m 2m 2m
IMMIX BIOPHARMA (IMMX)
NASDAQ
$8.63+$0.26 (+3.11%)
Price as of Jun 03, 2026 7:41 PM EDT- $640.7MMarket Cap
- 296.45%1-Year Change
- BiotechnologyIndustry
IMMIX BIOPHARMA (IMMX)
$8.63+$0.26 (+3.11%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 0 N/A | 0 N/A | 0 N/A | 0 N/A | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -16.3M +43.97% | -11.3M +29.28% | -8.7M +108.19% | -4.2M +3,216.11% | |
Depreciation and Amortization Expense | 245,747 +646.02% | 32,941 +502.43% | 5,468 +156.11% | 2,135 -13.49% | |
Total Operating Expenses | 30.0M +32.11% | 22.7M +40.48% | 16.1M +96.39% | 8.2M +507.90% | |
Operating Profit | -30.0M +32.11% | -22.7M +40.48% | -16.1M +96.39% | -8.2M +507.90% | |
Interest Income | 555,526 -45.40% | 1.0M +77.86% | 572,006 N/A | N/A N/A | |
Interest Expense | N/A N/A | N/A N/A | N/A N/A | -497 -99.72% | |
Interest Income and Expense and Net | 555,526 -45.40% | 1.0M +77.86% | 572,006 +115,191.75% | -497 -99.72% | |
Total Nonoperating Income and Expense | 555,526 -45.40% | 1.0M +77.86% | 572,006 +115,191.75% | -497 -100.00% | |
Income before Taxes | -29.4M +35.75% | -21.7M +39.10% | -15.6M +89.42% | -8.2M -66.28% | |
Income Taxes | 37,724 -8.07% | 41,037 +55.35% | 26,415 +157.26% | 10,268 +70.76% | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -29.4M +36.21% | -21.6M +40.11% | -15.4M +87.44% | -8.2M -66.25% | |
Net Income from Continuing Operations Applicable to Common | -29.4M +35.75% | -21.7M +39.10% | -15.6M +89.42% | -8.2M -66.28% | |
Basic EPS and Net Income | -0.89 +17.11% | -0.76 -14.61% | -0.89 +50.85% | -0.59 -91.11% | |
Diluted EPS and Net Income | -0.89 +17.11% | -0.76 -14.61% | -0.89 +50.85% | -0.59 -91.11% | |
Basic Weighted Average Shares | 33.0M +16.55% | 28.3M +63.11% | 17.3M +24.87% | 13.9M +278.13% | |
Diluted Weighted Average Shares | 33.0M +16.55% | 28.3M +63.11% | 17.3M +24.87% | 13.9M +278.13% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 93.9M +431.21% | 17.7M +0.98% | 17.5M +30.31% | 13.4M -23.85% | |
Short-Term Investments | 6.5M N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 100.4M +467.86% | 17.7M +0.98% | 17.5M +30.31% | 13.4M -23.85% | |
Total Current Assets | 101.2M +401.23% | 20.2M +2.07% | 19.8M +32.82% | 14.9M -18.08% | |
Accumulated Depreciation | 293,001 +520.04% | 47,255 N/A | N/A N/A | N/A N/A | |
Property and Plant and Equipment and Net | 2.5M +44.91% | 1.7M +3,367.74% | 50,181 +1,309.58% | 3,560 -37.49% | |
Total Long-Term Assets | 20,418 0.00% | 20,418 -85.14% | 137,410 +1,943.58% | 6,724 +18.07% | |
Total Assets | 104.8M +356.86% | 22.9M +15.17% | 19.9M +33.65% | 14.9M -18.05% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 10.1M +16.39% | 8.7M +133.41% | 3.7M +192.30% | 1.3M +530.22% | |
Total Long-Term Debt | 2.1M 0.00% | 2.1M 0.00% | 2.1M -2.78% | 2.2M +764.00% | |
Total Long-Term Liabilities | 933,625 -7.52% | 1.0M N/A | N/A N/A | N/A N/A | |
Total Liabilities | 11.0M +13.90% | 9.7M +160.54% | 3.7M +112.88% | 1.7M +765.33% | |
Retained Earnings | -104.5M +39.24% | -75.0M +40.47% | -53.4M +40.61% | -38.0M +27.66% | |
Total Stockholders Equity | N/A N/A | 13.3M -19.23% | 16.4M +24.66% | 13.2M -26.85% | |
Total Shares Outstanding | 53.0M +92.27% | 27.5M +38.24% | 19.9M +43.41% | 13.9M +5.02% | |
Cash Flow | |||||
Cash from Operating Activities | -23.9M +63.96% | -14.6M +28.35% | -11.4M +53.50% | -7.4M +366.13% | |
Capital Expenditures | 732,925 -37.77% | 1.2M +2,160.90% | 52,089 N/A | N/A N/A | |
Cash from Investing Activities | -7.2M +512.54% | -1.2M +2,160.90% | -52,089 N/A | N/A N/A | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 107.4M +573.33% | 15.9M +3.14% | 15.5M +378.44% | 3.2M -82.85% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Return on Assets | -46.07% -54.30% | -100.82% +13.84% | -88.57% +78.12% | -49.73% N/A | |
Return on Equity | N/A N/A | -145.76% +39.68% | -104.35% +97.49% | -52.84% N/A | |
Revenue Growth | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Current Ratio | 10.01 +330.67% | 2.33 -56.27% | 5.32 -54.56% | 11.70 N/A | |
Cash Ratio | 9.29 +356.43% | 2.04 -56.74% | 4.70 -55.42% | 10.55 N/A | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow